'MabThera Confirmed As Beneficial For Treating Non-Hodgkin's Lymphoma' Medical News Today The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded, after conducting a quality review of the genetically engineered monoclonal antibody MabThera, that the batches of rituximab, the active substance of ... |
